Novavax Inc - Asset Resilience Ratio
Novavax Inc (NVAX) has an Asset Resilience Ratio of 55.24% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NVAX working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how Novavax Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Novavax Inc (NVAX) total assets.
Liquid Assets Composition Over Time
This chart breaks down Novavax Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Novavax Inc (NVAX) long-term investment share to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $527.88 Million | 55.24% |
| Total Liquid Assets | $527.88 Million | 55.24% |
Asset Resilience Insights
- Very High Liquidity: Novavax Inc maintains exceptional liquid asset reserves at 55.24% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Novavax Inc Industry Peers by Asset Resilience Ratio
Compare Novavax Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Novavax Inc (2006–2025)
The table below shows the annual Asset Resilience Ratio data for Novavax Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 42.03% | $494.45 Million | $1.18 Billion | +16.85pp |
| 2024-12-31 | 25.18% | $392.89 Million | $1.56 Billion | +24.60pp |
| 2023-12-31 | 0.58% | $10.42 Million | $1.80 Billion | -- |
| 2021-12-31 | 0.00% | $0.00 | $2.58 Billion | -- |
| 2020-12-31 | 9.96% | $157.65 Million | $1.58 Billion | -- |
| 2019-12-31 | 0.00% | $0.00 | $172.96 Million | -- |
| 2018-12-31 | 10.57% | $21.98 Million | $207.98 Million | -6.29pp |
| 2017-12-31 | 16.86% | $51.00 Million | $302.49 Million | -6.25pp |
| 2016-12-31 | 23.11% | $91.13 Million | $394.30 Million | -12.52pp |
| 2015-12-31 | 35.63% | $137.55 Million | $386.04 Million | -13.54pp |
| 2014-12-31 | 49.17% | $135.72 Million | $276.00 Million | +43.41pp |
| 2013-12-31 | 5.76% | $13.60 Million | $235.94 Million | -20.34pp |
| 2012-12-31 | 26.10% | $26.71 Million | $102.34 Million | +19.78pp |
| 2011-12-31 | 6.32% | $4.21 Million | $66.58 Million | -25.24pp |
| 2010-12-31 | 31.55% | $23.61 Million | $74.84 Million | +26.65pp |
| 2009-12-31 | 4.90% | $4.19 Million | $85.61 Million | -4.19pp |
| 2008-12-31 | 9.09% | $6.96 Million | $76.62 Million | -37.07pp |
| 2007-12-31 | 46.16% | $42.14 Million | $91.29 Million | -8.35pp |
| 2006-12-31 | 54.51% | $66.43 Million | $121.88 Million | -- |
About Novavax Inc
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Com… Read more